Loading...
XASXRCE
Market cap68mUSD
Jan 06, Last price  
0.48AUD
1D
0.00%
1Q
-11.21%
Jan 2017
187.88%
IPO
55.74%
Name

Recce Pharmaceuticals Ltd

Chart & Performance

D1W1MN
XASX:RCE chart
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
13.17%
Rev. gr., 5y
34.10%
Revenues
0k
-100.00%
38797,142113,854177,020139,2951,288,518679,6241,121,7271,637,3823,084,9554,365,2160
Net income
-18m
L+35.06%
-292,460-272,416-450,166-4,840,358-3,025,504-1,674,288-2,789,197-4,316,737-13,513,366-10,986,277-13,077,422-17,661,714
CFO
-13m
L+2.53%
011,429-296,137-1,607,608-2,497,867-1,732,317-2,612,131-3,807,450-7,855,849-9,010,263-12,687,370-13,008,658
Earnings
Feb 25, 2025

Profile

Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic anti–infectives in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer anti-infective. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.
URL
https://www.recce.com.au/
IPO date
Jan 15, 2016
Employees
Domiciled in
AU
Incorporated in
AU

Valuation

Title
AUD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
4,365
41.50%
3,085
88.41%
Cost of revenue
367
12,615
9,778
Unusual Expense (Income)
NOPBT
(367)
(8,250)
(6,694)
NOPBT Margin
Operating Taxes
(4,906)
(4,311)
(3,085)
Tax Rate
NOPAT
4,539
(3,939)
(3,609)
Net income
(17,662)
35.06%
(13,077)
19.03%
(10,986)
-18.70%
Dividends
Dividend yield
Proceeds from repurchase of equity
11,146
102
(1,431)
BB yield
-10.49%
-0.09%
0.91%
Debt
Debt current
224
148
75
Long-term debt
1,398
205
89
Deferred revenue
Other long-term liabilities
237
192
101
Net debt
(2,793)
(1,208)
(11,418)
Cash flow
Cash from operating activities
(13,009)
(12,687)
(9,010)
CAPEX
(142)
(39)
(40)
Cash from investing activities
(142)
(39)
(40)
Cash from financing activities
16,004
2,706
(240)
FCF
10,869
(1,354)
(3,547)
Balance
Cash
4,415
1,562
11,582
Long term investments
Excess cash
4,415
1,343
11,428
Stockholders' equity
(9,524)
(2,589)
10,061
Invested Capital
1,048
443
190
ROIC
609.11%
ROCE
4.33%
384.41%
EV
Common stock shares outstanding
177,100
175,714
175,871
Price
0.60
-4.00%
0.63
-29.78%
0.89
-4.30%
Market cap
106,260
-3.24%
109,821
-29.84%
156,525
7.23%
EV
103,467
108,613
145,107
EBITDA
(367)
(8,033)
(6,506)
EV/EBITDA
Interest
847
183
12
Interest/NOPBT